title: The effect of valdecoxib on the production of growth factors evoked by hypoxia and bacterial lipopolysaccharide in HMEC-1 cells.
abstract: BACKGROUND
  Endothelial cells produce prostaglandins (PGE2 and PGI2) and growth factors (VEGF and bFGF). These substances regulate proliferation of cells, inflammatory processes and neovascularization under physiological and pathological conditions.
  
  
  OBJECTIVE
  The aim of this study was to check whether valdecoxib - a selective COX-2 inhibitor - inhibits VEGF and/or bFGF secretion in the presence of LPS or cobalt chloride in normal human microvascular endothelial cells (HMEC-1).
  
  
  METHODS
  HMEC-1 cells were treated with valdecoxib at a concentration of 10 and 100 μM in the presence of 100 μg/mL LPS or 200 μM CoCl2. The effect of NSAIDs and LPS on VEGF and bFGF proteins was analyzed by ELISA kit (R&D Systems). Cell viability was measured using the 3-[4.5-dimethylthiazol-2-yl]-2.5-diphenyltetrazolium bromide (MTT) method.
  
  
  RESULTS
  Valdecoxib inhibited LPS-induced proliferation of endothelial cells and bFGF secretion in a dose-dependent manner. Valdecoxib stimulated VEGF formation via HMEC-1 under inflammatory conditions.
authors.affiliation: Department of Pharmacology, Chair of Pharmacology and Clinical Pharmacology, Medical University of Lodz, Poland.
authors.forename: Anna
authors.initials: A
authors.lastname: Wiktorowska-Owczarek
mesh_terms: D015687:Cell Hypoxia; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D003035:Cobalt / Q000494:pharmacology; D052246:Cyclooxygenase 2 Inhibitors / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D042783:Endothelial Cells / Q000378:metabolism*; D016222:Fibroblast Growth Factor 2 / Q000096:biosynthesis*; D006801:Humans; D007555:Isoxazoles / Q000494:pharmacology*; D008070:Lipopolysaccharides / Q000494:pharmacology*; D013449:Sulfonamides / Q000494:pharmacology*; D042461:Vascular Endothelial Growth Factor A / Q000096:biosynthesis*; D000096926:Benzenesulfonamides
chemical_list: D003035:Cobalt; D052246:Cyclooxygenase 2 Inhibitors; D016222:Fibroblast Growth Factor 2; D007555:Isoxazoles; D008070:Lipopolysaccharides; D013449:Sulfonamides; D042461:Vascular Endothelial Growth Factor A; C406224:valdecoxib; D000096926:Benzenesulfonamides; C018021:cobaltous chloride